We are thrilled to welcome Matt to our leadership team,” said Allan Reine, M.D., Chief Executive Officer of Prime Medicine. “Business development has been – and will continue to be – a core pillar of ...
Thankfully, some companies can handle an inflationary environment and perform well throughout, while still registering the 12 ...
Explore how Leen Kawas redefines support ecosystems for biotech entrepreneurs beyond traditional funding methods.
Vistagen , a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called ...
Mosti is using Budget 2026 to advance its 'From Lab to Livelihood' agenda as a catalyst for national economic growth and innovation.
Geron Corporation , a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that five abstracts ? one oral and four poster ...
The Rising Wave of Esoteric Testing The Esoteric Testing Market represents a specialized segment of diagnostic laboratory services that focuses on rare and complex tests not routinely performed in ...
Alphabet released earnings that surpassed analysts’ estimates. The company’s cloud business offers customers a variety of AI products and services, including access to those from Nvidia. Nvidia ...
Hosted on MSN
There’s a bigger story in the OpenAI for-profit news
This story was first featured in the Future Perfect ... can’t deliver its benefits in isolation for now — there has to be continued investment in the other structures that drive change. AI is part of ...
The biotechnology market is entering a new growth phase, driven by the convergence of genomic science, artificial intelligence, and precision medicine.
Krystal Biotech, Inc. (the "Company”) (NASDAQ: KRYS) today reported financial results for the third quarter ending September 30, 2025 and provided a business update. "It is immensely gratifying to see ...
Lumen Biosciences Brian Finrow breaks down Chinas biotech playbook and explores ways the U.S. can adapt it for its own continued success.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback